Conavi Medical Receives FDA Clearance for First Hybrid IVUS-OCT Intravascular Imaging System
核心洞察
Conavi Medical (搜索) received FDA 510(k) clearance for its next-generation hybrid imaging system that integrates IVUS and OCT technologies into a single platform for coronary artery assessment.
The system enables simultaneous visualization of deep vessel structures and high-resolution surface detail in real time, streamlining workflows and supporting physician decision-making during percutaneous coronary interventions.
The company plans to initiate U.S. commercial launch in the second half of 2026, targeting a global intravascular imaging market estimated to exceed $4 billion annually.
Conavi Medical (搜索) Corp. has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its next-generation hybrid imaging system, marking the first co-registered and co-aligned IVUS-OCT platform for intravascular imaging. The clearance positions the Toronto-based medical device company to launch commercially in the U.S. market during the second half of 2026.
Revolutionary Hybrid Technology
The system integrates intravascular ultrasound (IVUS) and optical coherence tomography (OCT) into a single platform, enabling physicians to visualize both deep vessel structures through IVUS and high-resolution surface detail via OCT in real time. This dual-modality approach is designed to support physician decision-making and streamline workflows during percutaneous coronary interventions.
"FDA clearance of our next-generation hybrid imaging system marks a pivotal moment for Conavi as we transition into commercial launch in the U.S.," said Thomas Looby, Chief Executive Officer of Conavi Medical (搜索). "We believe hybrid IVUS-OCT imaging represents the next evolution in intravascular imaging, bringing together IVUS and OCT into a single system to give a complete picture of the vessel."
Clinical Impact and Workflow Enhancement
Dr. Megha Prasad, Interventional Cardiologist at New York-Presbyterian Hospital (搜索), highlighted the clinical potential of the technology. "Hybrid IVUS-OCT imaging has the potential to meaningfully enhance how we approach complex coronary interventions," she said. "The ability to simultaneously evaluate plaque composition, vessel size, and stent expansion in a single pullback can support procedural decision-making and workflow efficiency."
The system addresses current limitations in intravascular imaging adoption by enabling simultaneous, co-registered IVUS and OCT imaging in a single pullback, providing lesion and stent analysis tools that incorporate insights from both imaging modalities, and eliminating the need for multiple imaging systems.
Market Opportunity and Growth Drivers
Intravascular imaging is increasingly recognized as a critical tool in percutaneous coronary intervention, with growing clinical evidence demonstrating improved outcomes when imaging is used to guide stent sizing and placement. However, adoption remains underpenetrated globally, in part due to workflow complexity and the need to use multiple imaging systems.
The global market opportunity for coronary intravascular imaging is estimated to exceed $4 billion annually, with IVUS and OCT penetration currently at 30-40% of eligible procedures and continuing to expand. Growth is being driven by increasing adoption of image-guided PCI procedures, expanding clinical evidence supporting improved patient outcomes, greater focus on optimizing stent placement and reducing repeat interventions, and continued integration of AI and advanced imaging technologies into clinical workflows.
Commercial Launch Strategy
Following FDA clearance, Conavi is actively preparing for U.S. commercialization with plans to initiate a limited market release in select U.S. centers in the second half of calendar 2026. The company is positioned to expand its hybrid intravascular imaging technology in what it describes as a growing intravascular imaging market estimated at over $1 billion in the U.S.
As healthcare systems continue to prioritize precision, efficiency, and outcomes, intravascular imaging has become one of the fastest-growing segments in interventional cardiology, positioning Conavi's hybrid system to address unmet needs in the evolving landscape of image-guided coronary care.